As of March 23, 2026, Aquestive Therapeutics's top three insider holders are Daniel Barber (President And Ceo, 1.00Mn shares), Alexander Mark Schobel (Chief Innovation/Tech Officer, 984.48K shares), Keith J Kendall (Ceo And President, 637.15K shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Daniel Barber | President And Ceo | 1,004,753 | 0 | 11 Mar, 2026 |
| Alexander Mark Schobel | Chief Innovation/Tech Officer | 984,476 | 0 | 19 Mar, 2024 |
| Keith J Kendall | Ceo And President | 636,149 | 1,000 | 27 Aug, 2021 |
| Lori J Braender | Chief Legal Officer | 442,879 | 0 | 11 Mar, 2026 |
| A Ernest Jr Toth | Chief Financial Officer | 376,112 | 0 | 11 Mar, 2026 |
| Stephen Wargacki | Chief Science Officer | 343,552 | 0 | 11 Mar, 2025 |
| Peter E. Boyd | Chief People Officer | 338,509 | 0 | 11 Mar, 2026 |
| Carl N Kraus | Chief Medical Officer | 282,475 | 0 | 16 Oct, 2025 |
| Cassie Jung | Chief Operating Officer | 274,980 | 0 | 11 Mar, 2026 |
| Melina Cioffi | Svp, Regulatory Affairs | 274,867 | 0 | 11 Mar, 2026 |
| Sherry Korczynski | Chief Commercial Officer | 241,117 | 0 | 11 Mar, 2026 |
| Douglas K Bratton | 0 | 199,841 | 04 Dec, 2024 | |
| Ken W. Marshall | Svp, Chief Commercial Officer | 150,000 | 0 | 09 Mar, 2023 |
| Matthew W. Davis | Chief Development Officer | 100,000 | 0 | 11 Mar, 2026 |
| John Cochran | 99,486 | 0 | 01 Jun, 2021 | |
| Matthew J. Greenhawt | Chief Medical Officer | 75,000 | 0 | 11 Mar, 2026 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 09 Mar, 2026 | Peter E. Boyd | Common Stock | A | 80,000 | $0.00 | 368,323 | D | A |
| 09 Mar, 2026 | Daniel Barber | Common Stock | A | 262,000 | $0.00 | 1,185,430 | D | A |
| 09 Mar, 2026 | Matthew W. Davis | Common Stock | A | 50,000 | $0.00 | 100,000 | D | A |
| 09 Mar, 2026 | Sherry Korczynski | Common Stock | A | 75,000 | $0.00 | 256,858 | D | A |
| 09 Mar, 2026 | Melina Cioffi | Common Stock | A | 100,000 | $0.00 | 300,178 | D | A |
| 09 Mar, 2026 | Lori J Braender | Common Stock | A | 80,000 | $0.00 | 482,981 | D | A |
| 09 Mar, 2026 | A Ernest Jr Toth | Common Stock | A | 95,000 | $0.00 | 434,366 | D | A |
| 09 Mar, 2026 | Cassie Jung | Common Stock | A | 80,000 | $0.00 | 320,771 | D | A |
| 09 Mar, 2026 | Matthew J. Greenhawt | Common Stock | A | 75,000 | $0.00 | 75,000 | D | A |
| 10 Mar, 2026 | Melina Cioffi | Common Stock | D | 25,311 | $4.17 | 274,867 | D | S |
| 10 Mar, 2026 | Sherry Korczynski | Common Stock | D | 15,741 | $4.17 | 241,117 | D | S |
| 10 Mar, 2026 | Daniel Barber | Common Stock | D | 180,677 | $4.17 | 1,004,753 | D | S |
| 09 Mar, 2026 | Matthew W. Davis | Non-Qualified Stock Option (right to buy) | A | 50,000 | $0.00 | 50,000 | D | A |
| 10 Mar, 2026 | Lori J Braender | Common Stock | D | 40,102 | $4.17 | 442,879 | D | S |
| 10 Mar, 2026 | Peter E. Boyd | Common Stock | D | 29,814 | $4.17 | 338,509 | D | S |
| 10 Mar, 2026 | A Ernest Jr Toth | Common Stock | D | 58,254 | $4.17 | 376,112 | D | S |
| 09 Mar, 2026 | A Ernest Jr Toth | Non-Qualified Stock Option (right to buy) | A | 70,000 | $0.00 | 70,000 | D | A |
| 09 Mar, 2026 | Peter E. Boyd | Non-Qualified Stock Option (right to buy) | A | 42,500 | $4.29 | 42,500 | D | A |
| 10 Mar, 2026 | Cassie Jung | Common Stock | D | 45,791 | $4.17 | 274,980 | D | S |
| 09 Mar, 2026 | Melina Cioffi | Non-Qualified Stock Option (right to buy) | A | 75,000 | $4.29 | 75,000 | D | A |